Delving into the Latest Updates on Beijing Eirene BIOTECH INC. with Synapse

Overview

Tags

Neoplasms

Other Diseases

Immune System Diseases

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Immune System Diseases	1
Infectious Diseases	1
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Monoclonal antibody	2

Top 5 Target	Count

CD39(Ectonucleoside triphosphate diphosphohydrolase 1)	2

I期临床研究：评价重组全人源抗CD39单克隆抗体JS019单次、多次静脉输注给药在高嗜酸粒细胞增多症受试者中的安全性、耐受性、PK/PD特征及免疫原性，为II期临床试验提供线索和证据。 II期临床研究：探索重组全人源抗CD39单克隆抗体JS019用于高嗜酸粒细胞增多症受试者的安全性、最佳剂量及疗效趋势，为Ⅲ期临床研究提供线索和证据。

[Translation]

Phase I clinical study: Evaluate the safety, tolerability, PK/PD characteristics and immunogenicity of single and multiple intravenous infusions of recombinant fully human anti-CD39 monoclonal antibody JS019 in subjects with hypereosinophilia, and provide clues and evidence for Phase II clinical trials. Phase II clinical study: Explore the safety, optimal dose and efficacy trend of recombinant fully human anti-CD39 monoclonal antibody JS019 in subjects with hypereosinophilia, and provide clues and evidence for Phase III clinical studies.

Start Date25 Dec 2024

Sponsor / Collaborator

Beijing Eirene BIOTECH INC.

CTR20222055

/ RecruitingPhase 1

重组全人源抗CD39单克隆抗体JS019单药在晚期实体瘤患者中的安全性、耐受性、药代动力学特征和初步有效性的I期临床研究

[Translation] A phase I clinical study of the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of the recombinant fully human anti-CD39 monoclonal antibody JS019 in patients with advanced solid tumors

评价JS019单药在晚期恶性实体瘤患者中的安全性和耐受性；确定JS019单药的最大耐受剂量（MTD）或最佳生物效应剂量（OBD）和II期临床研究推荐剂量（RP2D）评价JS019单药在晚期恶性实体瘤患者中的药代动力学（PK）特征评价JS019单药在晚期恶性实体瘤患者中的免疫原性；评价JS019单药在晚期恶性实体瘤患者体内的药效学特征；初步评估JS019单药治疗晚期恶性实体瘤的有效性。

[Translation]

Evaluate the safety and tolerability of JS019 monotherapy in patients with advanced malignant solid tumors; Determine the maximum tolerated dose (MTD) or best biological effect dose (OBD) of JS019 monotherapy and the recommended dose (RP2D) for Phase II clinical studies Evaluate the pharmacokinetic (PK) characteristics of JS019 monotherapy in patients with advanced malignant solid tumors Evaluate the immunogenicity of JS019 monotherapy in patients with advanced malignant solid tumors; Evaluate the pharmacodynamic characteristics of JS019 monotherapy in patients with advanced malignant solid tumors; Preliminary evaluation of the effectiveness of JS019 monotherapy in the treatment of advanced malignant solid tumors.

Start Date09 Sep 2022

Sponsor / Collaborator

Suzhou Kebo Ruijun Biosciences Co. Ltd.

CTR20220434

/ RecruitingPhase 1

重组全人源抗CD39单克隆抗体JS019单药在晚期实体瘤或淋巴瘤患者中的安全性、耐受性、药代动力学特征和初步有效性的I期临床研究

[Translation] A phase I clinical study of the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of JS019, a recombinant fully human anti-CD39 monoclonal antibody, in patients with advanced solid tumors or lymphomas

评价JS019单药在晚期恶性实体瘤/淋巴瘤患者中的安全性和耐受性；确定JS019单药的最大耐受剂量（MTD，如果可能）和II期临床研究推荐剂量（RP2D）评价JS019单药在晚期恶性实体瘤/淋巴瘤患者中的药代动力学（PK）特征；评价JS019单药在晚期恶性实体瘤/淋巴瘤患者中的免疫原性；评价JS019单药在晚期恶性实体瘤/淋巴瘤患者体内的药效学特征；初步评估JS019单药治疗晚期恶性实体瘤/淋巴瘤的有效性探索相关生物标志物与疗效间的相关性

[Translation]

Evaluate the safety and tolerability of JS019 monotherapy in patients with advanced malignant solid tumors/lymphomas; Determine the maximum tolerated dose (MTD, if possible) and recommended dose (RP2D) of JS019 monotherapy for Phase II clinical studies Evaluate the pharmacokinetic (PK) characteristics of JS019 monotherapy in patients with advanced malignant solid tumors/lymphomas; Evaluate the immunogenicity of JS019 monotherapy in patients with advanced malignant solid tumors/lymphomas; Evaluate the pharmacodynamic characteristics of JS019 monotherapy in patients with advanced malignant solid tumors/lymphomas; Preliminary evaluation of the effectiveness of JS019 monotherapy in the treatment of advanced malignant solid tumors/lymphomas Explore the correlation between relevant biomarkers and efficacy

Start Date14 Apr 2022

Sponsor / Collaborator

Suzhou Kebo Ruijun Biosciences Co. Ltd.

100 Clinical Results associated with Beijing Eirene BIOTECH INC.

Login to view more data

0 Patents (Medical) associated with Beijing Eirene BIOTECH INC.

Login to view more data

100 Deals associated with Beijing Eirene BIOTECH INC.

Login to view more data

100 Translational Medicine associated with Beijing Eirene BIOTECH INC.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 14 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Phase 2 Clinical

Login to view more data